Somatic Genetic Alterations in Vascular Anomalies
This activity has been archived and credit is no longer available.
In this presentation, Dr. Ionela Iacobas discusses her collaborative research on the potential benefits of conducting somatic genetic testing in patients with vascular anomalies. She reviews the various clinical presentations of patients with vascular anomalies and identifies targeted therapy for particular somatic activating mutations that may be found in these patients.
This Clinical Genetics Conference session took place on Monday, March 28, 2022 at 4:00 P.M.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
Clinical geneticists, residents, fellows, laboratory fellows, genetic counselors, nurse practitioners, nurses, and medical students need to be regularly updated on the advances in clinical genetics research, and guidelines for the diagnosis and management of genetic disorders. The series aims to increase knowledge of the learners in these topic areas, and to provide the skills and tools for their implementation in clinical practice in order to enhance the quality of health care and outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Recognize the clinical presentations of patients of vascular anomalies that may benefit from somatic genetic testing.
- Identify targeted medical therapy for somatic activating mutations in PIK3CA/Akt1/mTOR pathway.
- Develop strategies for collaboration opportunities between basic and translational research labs at Baylor College of Medicine and the large patient cohort managed by the TCH Vascular Anomalies Center.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Nurses
- Other Health Professionals
Specialties
- Medical Genetics and Genomics
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
March 1, 2022 through March 31, 2024. Original release date: March 1, 2022.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Ionela Iacobas, M.D.
Associate Professor
Baylor College of Medicine, Texas Children's Hospital
Disclosure:
- Research Support: Merck; Novartis
Activity Director
-
Seema R. Lalani, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
- Intellectual Property: UpToDate® (Wolters Kluwer Health)
Planning Committee Members
-
Runjun Kumar, M.D., Ph.D.
Molecular and Human Genetics Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Seema R. Lalani, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
- Intellectual Property: UpToDate® (Wolters Kluwer Health)
-
Roni Zemet Lazar, M.D.
Molecular & Human Genetics Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Pilar L. Magoulas, M.S., CGC
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Chaya N. Murali, M.D.
Pediatric Geneticist
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: